Aimed Bio Inc. (KOSDAQ:0009K0)

South Korea flag South Korea · Delayed Price · Currency is KRW
56,300
-4,200 (-6.94%)
At close: Mar 19, 2026
Market Cap3.58T
Revenue (ttm)29.65B +17,218.1%
Net Income-43.02B
EPS-1,065.74
Shares Out64.67M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume459,618
Average Volume1,255,257
Open57,800
Previous Close60,500
Day's Range56,100 - 59,000
52-Week Range42,000 - 80,200
Betan/a
RSI45.35
Earnings DateMar 30, 2026

About Aimed Bio

Aimed Bio Inc. develops therapeutic solutions for patients with brain diseases, including neuro-oncological and degenerative diseases. Its multidisciplinary platform offers antibody-drug conjugates, blood-brain barrier penetration, brain immune modulation, and patient-derived models (PDC/PDX). Aimed Bio Inc. was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 0009K0
Full Company Profile

Financial Performance

In 2024, Aimed Bio's revenue was 11.76 billion, an increase of 6768.70% compared to the previous year's 171.21 million. Losses were -3.30 billion, -63.38% less than in 2023.

Financial Statements